Minimally invasive treatment for eyelid cholesterol deposits
Part of Hormones & metabolism clinical trials.
This trial tests a new minimally invasive procedure using tiny tunnels and a heparin injection to treat xanthelasma (cholesterol deposits under the skin of the eyelids). It may help reduce the appearance of these deposits with less scarring than traditional methods.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be diagnosed with xanthelasma (cholesterol deposits on your eyelids).
- You must be willing to receive an injection of heparin sodium as part of the treatment.
- You cannot have hemophilia (a bleeding disorder that prevents blood from clotting normally).
- You cannot have coronary heart disease (narrowing of the heart arteries).
- You cannot have had a heart attack (myocardial infarction).
- You cannot have had a stroke (cerebral infarction).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a cream containing simvastatin (commonly a cholesterol pill, now as a cream) to see if it can shrink fatty deposits on the eyelids. If you have these yellowish patches, using the cream might help reduce them without needing a procedure.
This Phase 3 study tests a medicine to help prevent abnormal calcium (called ectopic mineralization) from building up in people with pseudoxanthoma elasticum (PXE). It aims to slow or reduce new damage over time.
This study tests whether intense pulsed light (a gentle light therapy) can safely and effectively treat a chalazion (a blocked oil gland on the eyelid) that is inflamed. It might help reduce the lump and speed up healing.
This trial tests whether starting a new cholesterol-lowering injection early helps people who recently had a heart-related event and a procedure to open blocked arteries. It aims to reduce future heart problems.
This trial tests a new medicine, Artisterol, to see if it can lower cholesterol in people with mildly high levels. It may be an option if you haven't tried other treatments or can't take statins.
This trial tests whether giving a cholesterol-lowering injection (called a PCSK9 inhibitor) early after a stroke helps improve recovery and lowers cholesterol. It is for people whose stroke is caused by narrowed arteries, not by heart problems.
Hear when a new Xanthelasma Palpebrarum trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.